• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肥厚型心肌病的现代观点——没有一种方法适用于所有人。

Modern Perspectives on Hypertrophic Cardiomyopathy-No One Size Fits All.

作者信息

Doliner Brett, Gaddar Hadeel, Kalil Ramsey, Postalian Alexander

机构信息

Department of Cardiology, The Texas Heart Institute, Houston, Texas.

Faculty of Medicine at the American University of Beirut, Beirut, Lebanon.

出版信息

Tex Heart Inst J. 2024 Aug 1;51(2). doi: 10.14503/THIJ-24-8423.

DOI:10.14503/THIJ-24-8423
PMID:39086311
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11292115/
Abstract

Despite substantial advances in the management of hypertrophic cardiomyopathy, advanced heart failure remains a major cause of morbidity in this patient population. This narrative review presents the case of a patient with hypertrophic obstructive cardiomyopathy who underwent alcohol septal ablation to frame a discussion of modern therapies for hypertrophic cardiomyopathy. The current treatment landscape includes medications, both old and new, and surgical and procedural interventions to relieve mechanical obstruction. Several promising new modalities for relieving obstruction are in the nascent stages of development.

摘要

尽管肥厚型心肌病的管理取得了重大进展,但晚期心力衰竭仍是该患者群体发病的主要原因。这篇叙述性综述介绍了一名肥厚型梗阻性心肌病患者接受酒精室间隔消融术的病例,以此展开对肥厚型心肌病现代治疗方法的讨论。当前的治疗格局包括新旧药物以及缓解机械性梗阻的手术和介入治疗。几种有前景的缓解梗阻的新方法正处于发展初期。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/73bc/11292115/6c163b945ca6/i1526-6702-51-2-e248423-f03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/73bc/11292115/819676b4c777/i1526-6702-51-2-e248423-f01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/73bc/11292115/65b75ad7e6f9/i1526-6702-51-2-e248423-f02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/73bc/11292115/6c163b945ca6/i1526-6702-51-2-e248423-f03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/73bc/11292115/819676b4c777/i1526-6702-51-2-e248423-f01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/73bc/11292115/65b75ad7e6f9/i1526-6702-51-2-e248423-f02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/73bc/11292115/6c163b945ca6/i1526-6702-51-2-e248423-f03.jpg

相似文献

1
Modern Perspectives on Hypertrophic Cardiomyopathy-No One Size Fits All.肥厚型心肌病的现代观点——没有一种方法适用于所有人。
Tex Heart Inst J. 2024 Aug 1;51(2). doi: 10.14503/THIJ-24-8423.
2
Alcohol septal ablation for hypertrophic obstructive cardiomyopathy: a systematic review of published studies.酒精间隔消融术治疗肥厚型梗阻性心肌病:已发表研究的系统评价
J Interv Cardiol. 2006 Aug;19(4):319-27. doi: 10.1111/j.1540-8183.2006.00153.x.
3
Pacing for drug-refractory or drug-intolerant hypertrophic cardiomyopathy.药物难治性或药物不耐受性肥厚型心肌病的起搏治疗
Cochrane Database Syst Rev. 2012 May 16;2012(5):CD008523. doi: 10.1002/14651858.CD008523.pub2.
4
Brazilian Multicenter Registry of Alcohol Septal Ablation for Patients with Symptomatic Hypertrophic Obstructive Cardiomyopathy - BRASA Registry.巴西症状性肥厚性梗阻性心肌病患者酒精间隔消融多中心注册研究——BRASA注册研究
Arq Bras Cardiol. 2025 May;122(6):e20240626. doi: 10.36660/abc.20240626.
5
A meta analysis of current status of alcohol septal ablation and surgical myectomy for obstructive hypertrophic cardiomyopathy.酒精间隔消融术与外科室间隔切除术治疗梗阻性肥厚型心肌病现状的荟萃分析
Catheter Cardiovasc Interv. 2016 Jul;88(1):107-15. doi: 10.1002/ccd.26293. Epub 2015 Nov 3.
6
Gender-Based Outcome Discrepancies in Patients Who Underwent Alcohol Septal Ablation or Septal Myectomy for Hypertrophic Obstructive Cardiomyopathy: A Systematic Review and Meta-Analysis.性别对接受酒精室间隔消融术或室间隔切除术治疗肥厚型梗阻性心肌病患者结局的影响:系统评价和荟萃分析。
Am J Cardiol. 2023 Dec 1;208:134-142. doi: 10.1016/j.amjcard.2023.09.033. Epub 2023 Oct 13.
7
Efficacy and safety of radiofrequency ablation for hypertrophic obstructive cardiomyopathy: a meta-analysis.射频消融治疗肥厚型梗阻性心肌病的疗效与安全性:一项荟萃分析。
Future Cardiol. 2025 Jun;21(8):611-619. doi: 10.1080/14796678.2025.2509368. Epub 2025 May 22.
8
Changes in left ventricular-aortic angulation are associated with the development of obstruction in hypertrophic cardiomyopathy.左心室-主动脉夹角的改变与肥厚型心肌病梗阻的发生有关。
J Thorac Cardiovasc Surg. 2025 Jul;170(1):190-199. doi: 10.1016/j.jtcvs.2024.06.022. Epub 2024 Jun 29.
9
Novel Techniques for Alcohol Septal Ablation in Hypertrophic Obstructive Cardiomyopathy With Complex Anatomy: A Case Series.复杂解剖结构的肥厚型梗阻性心肌病酒精间隔消融新技术:病例系列
Catheter Cardiovasc Interv. 2025 Jul;106(1):349-354. doi: 10.1002/ccd.31549. Epub 2025 Apr 24.
10
A systematic review and meta-analysis of the efficacy and safety of Mavacamten therapy in international cohort of 524 patients with hypertrophic cardiomyopathy.马伐卡坦治疗524例肥厚型心肌病国际队列患者疗效和安全性的系统评价与荟萃分析。
Heart Fail Rev. 2024 Mar;29(2):479-496. doi: 10.1007/s10741-023-10375-6. Epub 2023 Dec 19.

引用本文的文献

1
Integrative Approaches in the Management of Hypertrophic Cardiomyopathy: A Comprehensive Review of Current Therapeutic Modalities.肥厚型心肌病管理中的综合方法:当前治疗方式的全面综述
Biomedicines. 2025 May 21;13(5):1256. doi: 10.3390/biomedicines13051256.

本文引用的文献

1
2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines.2024 年美国心脏协会/美国心脏病学会/美国运动医学会/心律学会/起搏与电生理学会/心血管磁共振学会肥厚型心肌病管理指南:美国心脏协会/美国心脏病学会临床实践指南联合委员会的报告。
J Am Coll Cardiol. 2024 Jun 11;83(23):2324-2405. doi: 10.1016/j.jacc.2024.02.014. Epub 2024 May 8.
2
Septal radioablation therapy for patients with hypertrophic obstructive cardiomyopathy: first-in-human study.肥厚性梗阻性心肌病患者的间隔放射性消融治疗:首例人体研究。
Eur Heart J Open. 2023 May 23;3(3):oead052. doi: 10.1093/ehjopen/oead052. eCollection 2023 May.
3
Cardiac Myosin Inhibitors for Managing Obstructive Hypertrophic Cardiomyopathy: JACC: Heart Failure State-of-the-Art Review.心肌球蛋白抑制剂治疗梗阻性肥厚型心肌病:美国心脏病学会心力衰竭最新临床实践综述。
JACC Heart Fail. 2023 Jul;11(7):735-748. doi: 10.1016/j.jchf.2023.04.018.
4
Alcohol septal ablation versus surgical septal myectomy of obstructive hypertrophic cardiomyopathy: systematic review and meta-analysis.酒精室间隔消融术与手术室间隔心肌切除术治疗梗阻性肥厚型心肌病的比较:系统评价和荟萃分析。
Eur J Cardiothorac Surg. 2023 Mar 1;63(3). doi: 10.1093/ejcts/ezad043.
5
Phase 2 Study of Aficamten in Patients With Obstructive Hypertrophic Cardiomyopathy.阿菲卡明治疗梗阻性肥厚型心肌病患者的2期研究。
J Am Coll Cardiol. 2023 Jan 3;81(1):34-45. doi: 10.1016/j.jacc.2022.10.020.
6
Dose-Blinded Myosin Inhibition in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy: Outcomes Through 32 Weeks.接受室间隔减容治疗的梗阻性肥厚型心肌病患者的剂量盲法肌球蛋白抑制:32周的结果
Circulation. 2023 Mar 14;147(11):850-863. doi: 10.1161/CIRCULATIONAHA.122.062534. Epub 2022 Nov 6.
7
Contemporary Therapies and Future Directions in the Management of Hypertrophic Cardiomyopathy.肥厚型心肌病治疗的当代疗法与未来方向
Cardiol Ther. 2022 Dec;11(4):491-507. doi: 10.1007/s40119-022-00283-5. Epub 2022 Oct 15.
8
Survival Following Alcohol Septal Ablation or Septal Myectomy for Patients With Obstructive Hypertrophic Cardiomyopathy.酒精间隔消融术或间隔心肌切除术治疗梗阻性肥厚型心肌病患者后的生存率
J Am Coll Cardiol. 2022 May 3;79(17):1647-1655. doi: 10.1016/j.jacc.2022.02.032.
9
Transcatheter Myotomy to Relieve Left Ventricular Outflow Tract Obstruction: The Septal Scoring Along the Midline Endocardium Procedure in Animals.经导管心肌切开术缓解左心室流出道梗阻:动物中线心内膜的间隔评分术。
Circ Cardiovasc Interv. 2022 Jun;15(6):e011686. doi: 10.1161/CIRCINTERVENTIONS.121.011686. Epub 2022 Apr 5.
10
Percutaneous Intramyocardial Septal Radiofrequency Ablation in Patients With Drug-Refractory Hypertrophic Obstructive Cardiomyopathy.经皮心肌内室间隔射频消融治疗药物难治性肥厚梗阻性心肌病。
JAMA Cardiol. 2022 May 1;7(5):529-538. doi: 10.1001/jamacardio.2022.0259.